Tafasitamab and lenalidomide in large B cell lymphoma: real-world outcomes in a multicenter retrospective study.
David A QuallsNicholas LambertPaolo F CaimiMwanasha H MerrillPriyanka PullarkatRichard C GodbyDavid A BondGraham T WehmeyerJason T RomancikBehzad AmoozgarLori A LeslieLoretta J NastoupilJennifer L CrombieJeremy S AbramsonArushi KhuranaGrzegorz S NowakowskiKami J MaddocksSarah C RutherfordBrad S KahlMichelle OkwaliMichael J BuegeVenkatraman E SeshanConnie Lee BatleviGilles Andre SallesPublished in: Blood (2023)
In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed/refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and overall survival, compared to the L-MIND registration clinical trial for TL.
Keyphrases
- free survival
- multiple myeloma
- clinical trial
- diffuse large b cell lymphoma
- newly diagnosed
- stem cell transplantation
- double blind
- acute lymphoblastic leukemia
- acute myeloid leukemia
- cross sectional
- study protocol
- open label
- phase ii
- hodgkin lymphoma
- randomized controlled trial
- metabolic syndrome
- high dose
- glycemic control
- placebo controlled